Most people regain a substantial share of the weight they lost after stopping semaglutide — trial follow-up found roughly two-thirds returned within the first year, leaving a net loss of about 5% versus pre-treatment weight. That's the average finding, not a worst case. It happens because appetite signalling returns to baseline once the drug clears, not because of a lack of discipline. And what comes back tends to be proportionally more fat than the lean mass that was lost — which is why the scale number doesn't tell you what actually changed. (Sources: STEP-1 trial extension and subsequent withdrawal analyses — verify figures against primary sources before publish.)

What the trial data actually shows

Let's start with the number, because most coverage either dodges it or garbles it.

In the extension of the STEP-1 trial, participants who came off semaglutide regained around two-thirds of the weight they had lost over the following year. Cardiometabolic markers that had improved on treatment — blood pressure, lipids, glycaemic measures — also drifted back toward their starting values.

There's a qualifier that gets dropped in the headlines, and it matters: participants were still, on average, around 5% below their pre-treatment weight a year after stopping. Two-thirds back is not all the way back. That residual isn't nothing, and pretending the result is total reversal is as inaccurate as pretending regain doesn't happen.

Later and broader analyses have added detail:

Across the most commonly used GLP-1 medications, an average of about 33 lb lost on treatment and roughly 22 lb regained within a year of stopping.
Reviews pooling multiple studies found most people returned to their starting weight within about 18 months.
Average regain works out to roughly 0.4 kg per month after discontinuation.
Regain after stopping medication proceeds around four times faster than regain after weight loss achieved through diet and exercise alone.

Editor note: every figure above must be traced to and cited from its primary source before publish, with a full reference block at the foot of the article. This page is intended to be citable by others — that only works if the citations are real and specific.

Is it the same for tirzepatide?

The pattern is similar for Mounjaro and Zepbound, but the numbers are not interchangeable. Tirzepatide withdrawal has its own trial evidence and should be cited separately rather than assumed to match semaglutide.

Editor note: cite the tirzepatide withdrawal data (SURMOUNT-4 or equivalent) directly for this section.

Why it happens — and why it isn't willpower

This is the part that matters most, because the framing people carry into it does real damage.

These medications don't fix appetite. They suppress it, continuously, for as long as you take them. GLP-1 receptor agonists slow gastric emptying and act on appetite and satiety signalling in the brain. That's the mechanism, and it's an ongoing effect, not a permanent recalibration. When the drug clears, the signalling returns to what it was.

Meanwhile, the physiology that defended your higher weight in the first place was never removed — only counteracted. Obesity behaves as a chronic, relapsing condition, and the body's regulatory systems continue to defend a higher set point. On medication, you were outcompeting that system. Off it, you're not.

So when hunger comes roaring back three weeks after your last injection, that isn't a character failure and it isn't you "letting it slip." It's the predictable consequence of removing an active intervention from a chronic condition. Nobody frames stopping blood-pressure medication as a personal failing when blood pressure rises again.

The half-life tail: why the first few weeks feel fine

Semaglutide has a half-life of roughly seven days. After your last dose, levels fall gradually over several weeks rather than dropping off a cliff.

That creates a deceptive window. For the first two or three weeks, you may feel largely unchanged — appetite still suppressed, eating patterns intact — and conclude you're one of the people it won't happen to. Then levels cross a threshold and appetite returns, often noticeably and often before the scale registers anything.

The common sequence people describe is: food noise returns first, eating volume increases second, weight follows third. If you want to see what the decline actually looks like after your last dose, Tiro's dosage plotter will draw it. And why food noise comes back covers that first signal in its own right.

What comes back isn't what you lost

This is the section almost nobody writes, and it's the most important one on the page.

Weight lost on a GLP-1 is not purely fat. Rapid weight loss — by any method, including these medications — includes a meaningful proportion of lean mass: muscle, and other non-fat tissue. That's expected, and it's why protein intake and resistance training are emphasised during treatment.

Weight regained after stopping tends to skew disproportionately toward fat.

Put those together and you get a result the bathroom scale is structurally incapable of showing you: you can return to your starting weight with less lean mass and more fat mass than when you began. Same number. Different body.

Editor note: this claim requires a peer-reviewed citation on body-composition changes during GLP-1 treatment and after discontinuation. Do not publish the asymmetry claim without it — it is the page's differentiator and it must be the best-sourced paragraph here.

Why it matters practically:

Lean mass is metabolically active. Less of it generally means a lower resting energy expenditure — which makes the next attempt harder than the last one.
Strength and function. Muscle is what carries the shopping, climbs the stairs, and protects you as you age. It isn't a cosmetic variable.
It's cumulative. Repeated cycles of loss and regain, each shifting the fat-to-lean ratio a little further, compound over years.

And the scale cannot see any of it. A person who has lost 30 lb of mostly fat while holding muscle and a person who has lost 30 lb with substantial muscle loss show the same number. So do the same two people a year after stopping.

This is the argument for tracking body composition rather than weight alone — measurements, a body scan, strength markers, how clothes fit. Not because the scale is useless, but because it's answering a different question from the one that matters here.

What the evidence supports doing about it

None of this is an argument for despair, and it isn't an argument for staying on medication forever either. Both of those are decisions above our pay grade. But there are levers with real support behind them.

Protein

Protein intake is the best-established dietary lever for preserving lean mass during weight loss. The working target for people on GLP-1 medications is roughly 1.2–1.6 g per kg of body weight per day — higher than general population guidance, because the loss is rapid and intake is suppressed.

The difficulty is practical: hitting that target while nauseated and full after a few bites is genuinely hard. How many grams of protein per meal deals with that specifically, and Tiro's protein calculator sets your daily floor.

This matters most during treatment and in the months after stopping — the lean mass you don't lose is the lean mass you don't have to rebuild.

Resistance training

The single strongest intervention for retaining lean mass. Not cardio — resistance work, at a stimulus sufficient to signal that the muscle is needed.

It doesn't require a gym membership or a complicated programme. It requires progressive loading, consistently, two or three times a week. Combined with adequate protein, it's the closest thing there is to insurance on this specific risk.

Maintenance dosing

For some people, staying on a lower maintenance dose rather than stopping entirely is an option their prescriber will discuss. It's an active area of clinical practice and it reframes the medication as ongoing management of a chronic condition rather than a finite course.

This is entirely a prescriber decision. We're not going to suggest a dose, and nobody writing an article should. See semaglutide maintenance dose after goal weight for how those conversations are usually structured.

Tapering rather than stopping abruptly

Whether a gradual step-down changes regain outcomes isn't well established — but it's commonly discussed, and it's a prescriber conversation worth having before your last injection rather than after. Our weaning off semaglutide guide covers the mechanics.

If you've already regained

If you're reading this after the fact, a few things worth saying plainly.

It isn't a moral event. You experienced the expected physiological response to withdrawing an effective treatment for a chronic condition. That's what the data describes happening to most people.

Prior response is informative. If the medication worked for you before, that's clinically useful information, not evidence you wasted your chance. Restarting is a legitimate conversation to have.

Restarting has its own rules. After a break, tolerance to the medication fades — most prescribers restart at a lower dose and re-titrate. Don't resume at your old dose. See stopping and restarting and the missed dose guide for what a long gap means.

Composition first, then the number. If you're restarting, protein and resistance training from day one — not as an afterthought at month six — change what the next round of loss is made of.

Frequently asked questions

Do you gain the weight back after stopping Ozempic? Most people regain a substantial share — around two-thirds within the first year in trial follow-up, leaving roughly 5% net loss versus pre-treatment. It's a physiological response, not a willpower failure.

How fast does it come back? Around 0.4 kg per month on average, with most people back at their starting weight within about 18 months. Appetite usually returns well before the scale moves.

Is it the same for Mounjaro and Zepbound? The pattern is similar; the specific figures differ. Check the tirzepatide evidence rather than assuming the semaglutide numbers apply.

Do you regain fat or muscle? Regain tends to skew toward fat, while the loss included lean mass — so the same weight doesn't mean the same body composition.

Can I prevent it? Protein at roughly 1.2–1.6 g/kg/day and resistance training are the best-supported levers for protecting lean mass. Maintenance dosing is a prescriber conversation.

Should I taper? Commonly discussed, and a decision for your prescriber — see our weaning guide for how step-downs are usually structured.

The scale can't see what actually changed

Body composition is the variable that matters here, and it's the one weight alone will never show you. Tiro tracks measurements and body composition alongside weight, so you can see whether you're losing fat or losing everything.

Set your protein floor → · Project your trajectory → · All Tiro GLP-1 tools →

Tiro is a tracker and companion app. It is not a treatment, does not prevent or reduce weight regain, does not diagnose, and does not replace your prescriber.

Ozempic Rebound: Two-Thirds Back in a Year — and Not the Same Body